Trial Profile

first-in-human dose-escalation study of TX45 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 31 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TX-000045 (Primary) ; TX-000045 (Primary)
Indications Cardiovascular disorders; Lung disorders
Focus Adverse reactions; First in man

Most Recent Events

18 Nov 2024 Results (n=55) assessing the tolerability and safety, immunogenicity, pharmacokinetic (PK) and pharmacodynamicof TX45 in healthy volunteers after single doses, presented at the American Heart Association Scientific Sessions 2024.
20 Jun 2024 According to a Tectonic Therapeutic media release, AVROBIO has been merged with Tectonic Therapeutic to form Tectonic Therapeutic.
30 Jan 2024 According to the AVROBIO media release, Following completion of the ongoing dose escalation safety and PK/PD studies in healthy volunteers, development of TX45 is planned to focus on an area of very high unmet need,

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com